Natixis Advisors LLC Purchases New Shares in Enovis Co. (NYSE:ENOV)

Natixis Advisors LLC purchased a new position in Enovis Co. (NYSE:ENOV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,680 shares of the company's stock, valued at approximately $546,000.

Other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its stake in shares of Enovis by 88.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company's stock worth $23,802,000 after acquiring an additional 179,276 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Enovis by 100.6% during the 1st quarter. Janus Henderson Group PLC now owns 378,020 shares of the company's stock valued at $23,606,000 after purchasing an additional 189,584 shares during the last quarter. Cetera Advisors LLC acquired a new stake in shares of Enovis in the 1st quarter worth $239,000. Boston Partners grew its stake in Enovis by 206.5% during the 1st quarter. Boston Partners now owns 295,969 shares of the company's stock worth $18,455,000 after buying an additional 199,411 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in Enovis during the 1st quarter valued at about $122,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. lowered their price target on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a report on Thursday, August 8th. Evercore ISI lowered their target price on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research note on Tuesday, October 1st. JMP Securities began coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Enovis has a consensus rating of "Moderate Buy" and an average price target of $67.00.

Enovis Stock Up 0.7 %

Shares of Enovis stock traded up $0.36 during trading on Friday, hitting $48.81. 249,656 shares of the company's stock were exchanged, compared to its average volume of 581,045. The business has a 50-day simple moving average of $43.08 and a 200-day simple moving average of $44.93. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter last year, the business posted $0.56 EPS. The company's revenue was up 21.0% on a year-over-year basis. As a group, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.